elbasvir
Jump to navigation
Jump to search
Indications
- in combination with grazoprevir for treatment-naive hepatitis C infection genotypes 1,4,6
Dosage
- 50 mg PO QD for 12 weeks in combination with grazoprevir 100 mg PO QD
Adverse effects
Mechanism of action
- antiviral protease inhibitor, inhibits NS5A
More general terms
Component of
References
- ↑ 1.0 1.1 Zeuzem S et al Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic HCV Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. Published online 24 April 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25909356 <Internet> http://annals.org/article.aspx?articleid=2279766